Therefore, to assess the relationship between DNAme and enhancers, we profiled bulk DNAme of normal B cell populations (peripheral blood naïve B cells [CD19+CD23+CD27−IgD+], n = 3; peripheral blood memory B cells [CD19+CD23+CD27+IgD−], n = 2) and CLL patient samples (IGHV unmutated, n = 2; IGHV mutated, n = 3) using a targeted bisulfite sequencing capture assay, which preferentially evaluates dynamic CpGs at gene-regulatory elements22 (Supplementary Fig. 1a, b; Supplementary Fig. 2a, b; Supplementary Data 4, 5). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.